Payment overview · 2025
General Payments
$347.76
16 reported records · 11 companies
Healthcare provider profile · identity verified
Drew Edward Rowan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COATESVILLE, PA · NPI 1285079384
Verified facts
What the public records show
CMS Open Payments records show Drew Edward Rowan, M.D. received $347.76 in general payments during 2025 across 16 reported records.
Janssen Biotech, Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $78.61 | 22.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.78 | 11.4% | 2 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $36.16 | 10.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.11 | 9.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.74 | 9.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.53 | 9.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.76 | 7.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.89 | 6.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.21 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.50 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.47 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $347.76 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $78.61 | 4 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $78.61 | 4 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $78.61 | 4 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $78.61 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.53 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 115 |
| Lisinopril | Lisinopril | 293 | 80 |
| Omeprazole | Omeprazole | 266 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 71 |
| Gabapentin | Gabapentin | 212 | 59 |
| Simvastatin | Simvastatin | 200 | 55 |
| Metformin Hcl | Metformin Hcl | 195 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 49 |
| Losartan Potassium | Losartan Potassium | 172 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 46 |
| Famotidine | Famotidine | 142 | 48 |
| Montelukast Sodium | Montelukast Sodium | 124 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 22 |
| Sertraline Hcl | Sertraline Hcl | 98 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 31 |
| Metformin Hcl Er | Metformin Hcl | 95 | 34 |
| Glipizide Er | Glipizide | 86 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 33 |
| Trazodone Hcl | Trazodone Hcl | 77 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 21 |
| Ezetimibe | Ezetimibe | 68 | 20 |
| Finasteride | Finasteride | 68 | 16 |
| Allopurinol | Allopurinol | 66 | 21 |
| Carvedilol | Carvedilol | 65 | 22 |
| Tramadol Hcl | Tramadol Hcl | 65 | 15 |
| Baclofen | Baclofen | 63 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 17 |
| Atenolol | Atenolol | 60 | 18 |
| Prednisone | Prednisone | 59 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 17 |
| Buspirone Hcl | Buspirone Hcl | 56 | 19 |
| Donepezil Hcl | Donepezil Hcl | 56 | 11 |
| Furosemide | Furosemide | 56 | 22 |
| Bupropion Xl | Bupropion Hcl | 54 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 12 |
| Jardiance | Empagliflozin | 45 | 14 |
| Meloxicam | Meloxicam | 43 | 25 |
| Ibuprofen | Ibuprofen | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Glimepiride | Glimepiride | 41 | 12 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Spironolactone | Spironolactone | 32 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Valsartan | Valsartan | 31 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Eliquis | Apixaban | 29 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Tadalafil | Tadalafil | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $347.76 · 16 records | Janssen Biotech, Inc. | ABRYSVO, CAPLYTA, COMIRNATY, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, REXULTI, SIMPONI, SIMPONI ARIA, STELARA, TRELEGY ELLIPTA, TREMFYA, VRAYLAR, Veozah, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error